Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given an average rating of “Hold” by the five research firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $3.33.

SYRS has been the subject of several recent analyst reports. Piper Sandler reissued an “overweight” rating and set a $5.00 price objective (down from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a report on Saturday. They set a “sell” rating for the company.

Syros Pharmaceuticals Stock Performance

Syros Pharmaceuticals stock opened at $0.24 on Friday. Syros Pharmaceuticals has a 12-month low of $0.18 and a 12-month high of $8.17. The company has a market capitalization of $6.54 million, a price-to-earnings ratio of -0.08 and a beta of 1.34. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The firm’s fifty day moving average price is $1.44 and its 200 day moving average price is $3.13.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter in the previous year, the company posted ($1.35) EPS. On average, research analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Activity

In other news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Jason Haas purchased 45,344 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was acquired at an average cost of $1.68 per share, with a total value of $76,177.92. Following the completion of the acquisition, the chief financial officer now directly owns 124,552 shares in the company, valued at approximately $209,247.36. This trade represents a 57.25 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after purchasing an additional 163,234 shares during the period. Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Certuity LLC acquired a new position in Syros Pharmaceuticals during the 2nd quarter valued at about $109,000. Finally, GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals during the 3rd quarter valued at about $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.